Medicare Blockades: Wegovy Coverage Challenge for Elderly Obese Patients

Despite federal healthcare decisions to cover Wegovy for obese patients at risk of heart disease, older Americans struggle to get prescriptions approved through Medicare. Doctors report low success rates with appeals, and the drug’s $1,300 monthly cost heightens calls for price reductions. The lack of widespread Medicare coverage persists despite clinical evidence of Wegovy’s heart disease benefits.

Elderly Americans face significant challenges in obtaining Medicare coverage for the weight-loss drug Wegovy, despite it being recommended for obese patients with heart disease risks. Physicians across the U.S. report low success rates for prescription approvals, with some experiencing numerous denials each month. Medicare's prohibition on covering 'lifestyle' drugs and the high cost of Wegovy, over $1,300 per month, spark calls for price reductions.

Clinical trials illustrate the drug’s benefits, such as a 20% reduction in heart attack and stroke risk. The U.S. Food and Drug Administration approved it for heart disease in March, leading the Centers for Medicare & Medicaid Services to issue guidance for coverage. However, only 1% of plans currently include Wegovy, leading to varied coverage even as some expect more plans to offer it next year.

Insurers emphasize it’s possible to access Wegovy for cardiovascular indications, but specifics on coverage remain vague. Analysts suggest plans might widen coverage, with companies like Novo and Eli Lilly lobbying for Medicare law changes. Meanwhile, physicians must prepare older patients for likely coverage denials as the demand among younger Americans with employer insurance surges.